Teva details Copaxone business
Israel's Teva Pharmaceutical Industries, in conjunction with the release of the Sanofi-Aventis group's financial results (Marketletter August 7), says that global in-market sales of Copaxone (glatiramer) reached a record $353.0 million in the second quarter ending June 30, 2006. Sanofi-Aventis markets the drug under license from Teva. Once again, Copaxone was the fastest-growing multiple sclerosis therapy worldwide, increasing 22% in sales over the comparable quarter of 2005.
US sales in the quarter rose 19% to $231.0 million and, according to IMS data, in the USA, Copaxone continued to strengthen its position as market leader reaching a market share of 33.9% in repeat and 34.9% in new prescriptions in June 2006.
Outside the USA, mainly in Europe, Copaxone continues to be the fastest-growing MS therapy with growth of 26% over the second quarter of 2005, reaching sales of $123.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze